Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort
Publié dansAnnals of the rheumatic diseases, vol. 79, no. 9, p. 1203-1209
Date de publication2020-09
Date de mise en ligne2020-06-24
Résumé
Mots-clés
- DMARDs (biologic)
- Ankylosing spondylitis
- Anti-TNF
- Spondyloarthritis
- Treatment
- Adult
- Antibodies, Monoclonal, Humanized / therapeutic use
- Antirheumatic Agents / therapeutic use
- Cohort Studies
- Comparative Effectiveness Research
- Drug Substitution
- Female
- Humans
- Male
- Middle Aged
- Severity of Illness Index
- Spondylarthritis / drug therapy
- Switzerland
- Treatment Outcome
- Tumor Necrosis Factor Inhibitors / therapeutic use
Structure d'affiliation
Groupe de recherche
Citation (format ISO)
MICHEROLI, Raphael et al. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. In: Annals of the rheumatic diseases, 2020, vol. 79, n° 9, p. 1203–1209. doi: 10.1136/annrheumdis-2019-215934
Fichiers principaux (1)
Article (Published version)
Identifiants
- PID : unige:163171
- DOI : 10.1136/annrheumdis-2019-215934
- PMID : 32581090
URL commercialhttps://ard.bmj.com/content/79/9/1203
ISSN du journal0003-4967